HEALTH● LOW1h ago · Sep 16, 2026, 1:21 PM
Novartis scraps ALS therapy after mid-stage trial setback
Seeking Alpha Tech · global
Novartis has discontinued its ALS therapy development after a setback in mid-stage trials. This decision impacts potential future treatments for Amyotrophic Lateral Sclerosis.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH14m agoXand van Tulleken on the 3 wellness trends to be most wary ofNew ScientistHEALTH16m agoRules tying doctors to rural posts leave Russian medical schools short of studentsEuroNews [en]HEALTHBREAKING49m agoBREAKING: There Are ‘Encouraging Signs’ In DR Congo Ebola Fight — WHOChannels TVHEALTH1h agoHealth authorities warn people with head injuries to avoid public waterbodiesThe Hindu